Ibrutinib(continued)
▶St John’s Wortis predicted to decrease the exposure to
ibrutinib. Avoid.rTheoretical
Ibuprofen→see NSAIDs
Icatibant
▶ACE inhibitorsare predicted to decrease the efficacy of
icatibantandicatibantis predicted to decrease the efficacy of
ACE inhibitors. Avoid.oTheoretical
Idarubicin→see anthracyclines
Idelalisib→seeTABLE 15p. 850 (myelosuppression)
▶Idelalisibis predicted to increase the exposure toabiraterone.
rTheoretical
▶Idelalisibis predicted to markedly increase the exposure to
aldosterone antagonists(eplerenone). Avoid.rStudy
▶Idelalisibincreases the exposure toalmotriptan.nStudy
▶Idelalisibis predicted to moderately increase the exposure to
alpha blockers(alfuzosin, tamsulosin). Use with caution or
avoid.oStudy
▶Idelalisibis predicted to increase the exposure toalpha blockers
(doxazosin).oStudy
▶Idelalisibmoderately increases the exposure toalprazolam.
Avoid.oStudy
▶Idelalisibis predicted to increase the exposure to
antiarrhythmics(amiodarone). Avoid.oTheoretical
▶Idelalisibvery markedly increases the exposure to
antiarrhythmics(dronedarone). Avoid.rStudy
▶Idelalisibis predicted to increase the exposure to
antiarrhythmics(propafenone). Monitor and adjust dose.r
Study
▶Idelalisibis predicted to increase the exposure to
anticholinesterases, centrally acting(galantamine). Monitor and
adjust dose.oStudy
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the exposure
toidelalisib. Avoid.rStudy
▶Idelalisibis predicted to very slightly increase the exposure to
antiepileptics(perampanel).nStudy
▶Idelalisibis predicted to increase the exposure toantifungals,
azoles(isavuconazole). Avoid or monitor side effects.r
Study
▶Idelalisibis predicted to increase the exposure to
antihistamines, non-sedating(mizolastine). Avoid.rStudy
▶Idelalisibis predicted to increase the exposure to
antihistamines, non-sedating(rupatadine). Avoid.oStudy
▶Idelalisibis predicted to increase the concentration of
antimalarials(piperaquine).rTheoretical
▶Idelalisibis predicted to markedly increase the exposure to
aprepitant.oStudy
▶Idelalisibis predicted to slightly increase the exposure to
aripiprazole. Adjustaripiprazoledose,p. 249.oStudy
▶Idelalisibis predicted to increase the exposure toaxitinib.
Avoid or adjust dose.oStudy→Also seeTABLE 15p. 850
▶Idelalisibis predicted to increase the exposure tobedaquiline.
Avoid prolonged use.nStudy
▶Idelalisibis predicted to increase the exposure tobeta 2 agonists
(salmeterol). Avoid.rStudy
▶Idelalisibslightly increases the exposure tobortezomib.
oStudy→Also seeTABLE 15p. 850
▶Bosentanis predicted to decrease the exposure toidelalisib.
Avoid.oTheoretical
▶Idelalisibis predicted to markedly increase the exposure to
bosutinib. Avoid or adjust dose.rStudy→Also seeTABLE 15
p. 850
▶Idelalisibis predicted to increase the exposure tobuspirone.
Adjustbuspironedose.rStudy
▶Idelalisibslightly increases the exposure tocabozantinib.
oStudy→Also seeTABLE 15p. 850
▶Idelalisibis predicted to increase the exposure tocalcium
channel blockers(amlodipine, felodipine, lacidipine, nicardipine,
nifedipine, nimodipine). Monitor and adjust dose.o
Study
▶Idelalisibis predicted to increase the exposure tocalcium
channel blockers(diltiazem, verapamil).rStudy
▶Idelalisibis predicted to markedly increase the exposure to
calcium channel blockers(lercanidipine). Avoid.rStudy▶Idelalisibis predicted to increase the exposure tocannabis
extract. Use with caution and adjust dose.oTheoretical
▶Idelalisibis predicted to increase the exposure toceritinib.
Avoid or adjustceritinibdose.rStudy→Also seeTABLE 15
p. 850
▶Idelalisibincreases the concentration ofciclosporin.r
Study
▶Idelalisibis predicted to moderately increase the exposure to
cilostazol. Adjustcilostazoldose.oStudy
▶Idelalisibis predicted to moderately increase the exposure to
cinacalcet. Adjust dose.oStudy
▶Idelalisibis predicted to markedly increase the exposure to
cobimetinib. Avoid or monitor for toxicity.rStudy
▶Idelalisibis predicted to increase the exposure tocolchicine.
Avoid potent inhibitors of CYP3A4 or adjustcolchicinedose.
rStudy
▶Idelalisibis predicted to increase the exposure to
corticosteroids(beclometasone)(risk with beclometasone is
likely to be lower than with other corticosteroids).o
Theoretical
▶Idelalisibis predicted to increase the exposure to
corticosteroids(betamethasone, budesonide, ciclesonide,
deflazacort, dexamethasone, fludrocortisone, fluticasone,
hydrocortisone, methylprednisolone, mometasone,
prednisolone, prednisone, triamcinolone). Avoid or monitor
side effects.rStudy
▶Idelalisibis predicted to moderately increase the exposure to
crizotinib. Avoid.oStudy→Also seeTABLE 15p. 850
▶Idelalisibis predicted to increase the exposure todabrafenib.
Use with caution or avoid.oStudy→Also seeTABLE 15
p. 850
▶Idelalisibis predicted to moderately increase the exposure to
daclatasvir. Adjustdaclatasvirdose.oStudy
▶Idelalisibis predicted to markedly to very markedly increase
the exposure todarifenacin. Avoid.rStudy
▶Idelalisibis predicted to markedly increase the exposure to
dasatinib. Avoid.rStudy→Also seeTABLE 15p. 850
▶Idelalisibvery slightly increases the exposure todelamanid.
rStudy
▶Idelalisibincreases the risk of QT-prolongation when given
withdomperidone. Avoid.rStudy
▶Idelalisibincreases the exposure todopamine receptor agonists
(bromocriptine).rStudy
▶Idelalisibis predicted to increase the concentration of
dopamine receptor agonists(cabergoline).oAnecdotal
▶Idelalisibis predicted to increase the exposure todutasteride.
Monitor side effects and adjust dose.oTheoretical
▶Efavirenzis predicted to decrease the exposure toidelalisib.
Avoid.oTheoretical
▶Idelalisibslightly to moderately increases the exposure to
elbasvir. Avoid.oStudy
▶Idelalisibis predicted to markedly increase the exposure to
eletriptan. Avoid.rStudy
▶Idelalisibis predicted to increase the exposure toeliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶Enzalutamideis predicted to decrease the exposure to
idelalisib. Avoid.rStudy
▶Idelalisibis predicted to increase the risk of ergotism when
given withergometrine. Avoid.rTheoretical
▶Idelalisibis predicted to increase the risk of ergotism when
given withergotamine. Avoid.rTheoretical
▶Idelalisibis predicted to slightly increase the exposure to
erlotinib. Use with caution and adjust dose.oStudy
▶Idelalisibis predicted to increase the concentration of
everolimus. Avoid.rStudy→Also seeTABLE 15p. 850
▶Idelalisibis predicted to moderately increase the exposure to
fesoterodine. Adjustfesoterodinedose with potent inhibitors
of CYP3A4; avoid in hepatic and renal impairment.r
Study
▶Idelalisibis predicted to increase the exposure to
fosaprepitant.oTheoretical
▶Idelalisibis predicted to increase the exposure togefitinib.
oStudy→Also seeTABLE 15p. 850
▶Idelalisibis predicted to moderately to markedly increase the
exposure tograzoprevir. Avoid.rStudy934 Ibrutinib—Idelalisib BNFC 2018 – 2019
Interactions|Appendix 1A1